BusinessFoundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2ABy Nasdaq OMXFeb 12, 2018, 12:01 PM UTC
BusinessProQR to Present at Upcoming Scientific Meeting and Investor ConferenceBy Nasdaq OMXFeb 6, 2018, 12:00 PM UTC
BusinessProQR Announces Presentations and Investor & Analyst Event at the North American Cystic Fibrosis ConferenceBy Nasdaq OMXOct 24, 2017, 11:00 AM UTC
